Azora Therapeutics, Inc. (AZR)
$4.88-3.37%Close
Snapshot
- 1 week
- +15.6%+14.9% vs SPY
- 1 month
- +17.6%+16.9% vs SPY
- Market cap
- $12.8M
Signal: Call, Regime, Alignment, Score, ATR trend, HiLo flip, Coil, Exhaustion, Topping · Technicals (EMA stack, slope, squeeze, stochastic, MACD-Z, DI+) · Price & returns: 3 months, Year to date, 1 year
Price & returns: 3 years, 5 years
Signal: Composite · Performance (Q-Score, Sharpe, Sortino, Calmar, CAGR, drawdown, alpha)
Signal evidence
Best Combo (today's action, held-out profit factor and family votes) · White Arrow (the call, its profit factor and closed trades) · Regime (today's regime and the regime model's profit factor) · Exhaustion (whether buyers or sellers are stretched today and the latest release)
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company
About
Azora Therapeutics, Inc. (AZR). Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
Profile
SectorHealthcare
IndustryMedical - Pharmaceuticals
ExchangeNASDAQ
CountryUS
CEOCary J. Claiborne
IPOJul 27, 2018
Employees6
Shares outstanding2.6M
Float2.4M
Free float-
Websiteazoratherapeutics.com
Snapshot
Price & returns1 month +17.6%
- 1 week
- +15.6%+14.9% vs SPY
- 1 month
- +17.6%+16.9% vs SPY
Valuationmarket cap $12.8M
- Market cap
- $12.8M
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company
About
Azora Therapeutics, Inc. (AZR). Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
Profile
SectorHealthcare
IndustryMedical - Pharmaceuticals
ExchangeNASDAQ
CountryUS
CEOCary J. Claiborne
IPOJul 27, 2018
Employees6
Shares outstanding2.6M
Float2.4M
Free float-
Websiteazoratherapeutics.com
Fundamentals
SCORES & PROFILE
FUND, Value, Growth and GARP scores and the archetype
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-
---
VALUATION
P/E TTM-
P/E FWD-
SECTOR PE20.99
INDUSTRY PE63.35
P/B-
P/FCF-
EV/EBITDA-
EV/EBIT-
FCF YIELD-
TRUE FCF YLD-
PEG-
Risk
INT COV-
D/E-
ALTMAN Z-
CURR RATIO-
ND/EBITDA-
Fundamentals
Scores & profile
FUND, Value, Growth and GARP scores and the archetype
ROIC-
Revenue YoY-
ROE-
EPS YoY-
ROA-
---
Valuation
P/E (TTM)-
P/E (forward)-
Sector P/E20.99
Industry P/E63.35
P/B-
P/FCF-
EV/EBITDA-
EV/EBIT-
FCF yield-
True FCF yield-
PEG-
Risk
Interest cover-
Debt/equity-
Altman Z-
Current ratio-
Net debt/EBITDA-
Company news
Loading headlines…